Bruno Angelici Joins The Board Of Vectura Group plc (VEC.L)

Chippenham, UK – 14 November 2013: Vectura Group plc (LSE: VEC; "Vectura" or "the Company") is delighted to announce the appointment of Bruno Angelici to the Board as an Independent Non-executive Director and Non-executive Chairman Designate. 

Bruno Angelici will join the Board on 1 December 2013 and will become Non-executive Chairman on 1 February 2014, the date on which current Chairman, Jack Cashman, will retire from the Board of Vectura. This follows the announcement on 23 September 2013, confirming the intention of Mr Cashman to retire after 12 years' service to the Board. 

Bruno Angelici is a Non-executive Director of Smiths Group plc, a FTSE 100 technology group, and Novo Nordisk A/S, a global healthcare company and world leader in diabetes care. He is also a member of the Global Advisory Board of Takeda Pharmaceutical Company Ltd Japan, the largest pharmaceutical company in Asia, and a member of the Supervisory Board of Wolters Kluwer NV, a global information services and publishing company. In the view of the Board, Bruno's exceptional knowledge, independence and extensive international experience at both board and senior management levels will be a significant addition to Vectura as the Company enters the next stage in its evolution. 

Bruno's career includes senior management roles in pharmaceutical and medical device companies. Bruno retired from AstraZeneca in 2010 as Executive Vice President International after a 20-year career. He was responsible for Europe, Japan, Asia Pacific, Latin America, Middle East and Africa having originally joined as President of ICI Pharma France. Prior to this, he was at Baxter, a US-based global supplier of medical devices. He has extensive international experience, including in the US, and brings a deep understanding to the Company of the medical device and pharmaceutical industries. 

Commenting on the new appointment, Jack Cashman, retiring Chairman of Vectura said, "I have greatly enjoyed my time at Vectura and value my experience on the Board and as Vectura's Chairman. I am delighted to be handing over leadership of the Board to Bruno Angelici who brings to Vectura a wealth of commercial and international experience, which will ensure Vectura's transition to a sustainably profitable business over the coming years." 

Bruno Angelici said: "I am delighted to be joining the Board of Vectura at such an exciting time in the evolution of the Company. I look forward to helping the Board chart the future success of Vectura." 

Dr Chris Blackwell, Chief Executive of Vectura added: "The departure of a formative member of the Company is always a sad time, but Jack leaves with our heart-felt gratitude and best wishes. We also extend a warm welcome to Bruno and look forward to working with him and the experience he brings to take Vectura through its next stage of development." 

There are no further details to disclose in accordance with Listing Rule LR9.6.13R. The appointment of Bruno Angelici follows a comprehensive search process using an independent search firm. 

Enquiries

Vectura Group plc +44 (0)1249 667700

Chris Blackwell, Chief Executive

Paul Oliver, Chief Financial Officer and Company Secretary

Karl Keegan, Corporate Development Director

FTI Consulting +44 (0)20 7831 3113

John Dineen / Ben Atwell

About Vectura

Vectura Group plc and its subsidiaries ("Vectura" or the "Group") is a product development company that focuses on the development of pharmaceutical therapies for the treatment of airway-related diseases. This growing market includes asthma and chronic obstructive pulmonary disease (COPD) and is estimated to be worth in excess of $30 billion worldwide. 

Vectura has seven products marketed by its partners and a portfolio of drugs in clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter, GlaxoSmithKline (GSK) and Tianjin King York Group Company Limited (KingYork). 

Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy. For further information, please visit Vectura's website at www.vectura.com. 

Suggested Articles

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.

The readout is a key moment in the history of the drug and Mirati, shares in which have soared in the updraft created by data on Amgen’s rival asset.